Search

Search Constraints

You searched for: Author/Creator Graef, Thorsten

Search Results

2. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. (2nd December 2018)

3. Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. (10th February 2019)

4. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Issue 8 (3rd August 2017)

5. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Issue 2 (February 2017)

6. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Issue 7 (July 2018)

7. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Issue 11 (2nd November 2018)

8. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. (13th February 2018)